Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement




May
24
Today In Oncology
Inavolisib-Based Regimen in PIK3CA-Mutated, HR-Positive, HER2-Negative Advanced Breast Cancer
GLP-1 RAs May Lower Risk of Obesity-Related Cancers
Extensive-Stage SCLC Lurbinectedin and Atezolizumab
Use of AI Assistance to Improve HER2 Breast Cancer Classifications
WGS Liquid Biopsies for HPV-Associated Head and Neck Squamous Cell Carcinoma
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo